ロード中...
Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells
BACKGROUND: mTOR inhibition of aromatase inhibitor (AI)-resistant breast cancer is currently under evaluation in the clinic. Everolimus/RAD001 (Afinitor®) has had limited efficacy as a solo agent but is projected to become part of combination therapy for AI-resistant breast cancer. This study was co...
保存先:
| 出版年: | BMC Cancer |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4947349/ https://ncbi.nlm.nih.gov/pubmed/27421652 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2490-z |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|